Until the results of ongoing pediatric RCTs [78] are published, treatment with an anti-CGRP/rec mAb in migraine patients below age 18 cannot be advocated without the abovementioned precautions and is not yet reimbursed in several countries. This evidence concerns the gene CALCA and migraine disorder.